Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy

Statin therapy reduces the risk of coronary heart disease (CHD), however, the person-to-person variability in response to statin therapy is not well understood. We have investigated the effect of genetic variation on the reduction of CHD events by pravastatin. First, we conducted a genome-wide assoc...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2012-05, Vol.7 (5), p.e38240-e38240
Main Authors: Shiffman, Dov, Trompet, Stella, Louie, Judy Z, Rowland, Charles M, Catanese, Joseph J, Iakoubova, Olga A, Kirchgessner, Todd G, Westendorp, Rudi G J, de Craen, Anton J M, Slagboom, P Eline, Buckley, Brendan M, Stott, David J, Sattar, Naveed, Devlin, James J, Packard, Christopher J, Ford, Ian, Sacks, Frank M, Jukema, J Wouter
Format: Article
Language:English
Subjects:
Aged
Analysis
Antilipemic agents
Cardiovascular agents
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Chromosomes
Coronary artery disease
Coronary Disease - drug therapy
Coronary Disease - genetics
Coronary Disease - prevention & control
Coronary heart disease
Disease control
Disease susceptibility
Female
Genetic aspects
Genetic diversity
Genetic Predisposition to Disease - genetics
Genetic research
Genome-wide association studies
Genome-Wide Association Study
Genomes
Genomics
Geriatrics
Health risks
Heart
Heart diseases
Homology
Humans
Low density lipoprotein
Male
Medicine
Middle Aged
Older people
Pharmacogenomics
Pharmacology
Polymorphism, Single Nucleotide
Pravastatin
Pravastatin - pharmacology
Pravastatin - therapeutic use
Prevention
Randomization
Risk
Single nucleotide polymorphisms
Single-nucleotide polymorphism
Statins
Studies
Therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statin therapy reduces the risk of coronary heart disease (CHD), however, the person-to-person variability in response to statin therapy is not well understood. We have investigated the effect of genetic variation on the reduction of CHD events by pravastatin. First, we conducted a genome-wide association study of 682 CHD cases from the Cholesterol and Recurrent Events (CARE) trial and 383 CHD cases from the West of Scotland Coronary Prevention Study (WOSCOPS), two randomized, placebo-controlled studies of pravastatin. In a combined case-only analysis, 79 single nucleotide polymorphisms (SNPs) were associated with differential CHD event reduction by pravastatin according to genotype (P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0038240